Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.
IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.
In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.
Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.
IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.
Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.
For more detailed updates and financial information, visit IDEAYA's Investor Relations page.
IDEAYA Biosciences (Nasdaq:IDYA) provided a business update and reported financial results for Q4 2020. The company advanced IDE397 into Phase 1 for treating solid tumors with MTAP deletions, representing about 15% of all solid tumors. IDEAYA's pipeline includes significant progress in IDE196 and plans for Development Candidate nominations for PARG and Pol Theta programs in 2021. Financially, IDEAYA reported a net loss of $5.1 million for Q4 2020, improved from $10.8 million in Q4 2019, and held $283.6 million in cash and equivalents as of December 31, 2020.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced a dose expansion of its Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma (MUM). Early clinical activity has shown promise, with plans to enroll approximately 40 patients. IDEAYA received a Notice of Allowance for a U.S. patent covering this combination therapy. The company targets interim data updates in 2021, including tolerability and clinical efficacy from both the combination and monotherapy arms, which may reveal clinical activity independent of HLA status.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the publication of abstracts for its synthetic lethality programs at the 2021 AACR Annual Meeting. The company will present data on IDE397, a MAT2A inhibitor, and IDE196, a PKC inhibitor targeting certain cancers. IDE397 is currently in a Phase 1 trial targeting tumors with MTAP deletion, while IDE196 is in Phase 1/2 trials for metastatic uveal melanoma and skin melanoma. The presentations will also cover preclinical data on the efficacy of these treatments and their potential combinations with other therapies.
IDEAYA Biosciences (NASDAQ: IDYA), a company focused on precision medicine in oncology, announced its participation in several significant investor relations events in March 2021. These include the H.C. Wainwright Global Life Sciences Conference on March 9, Citi's Winter West Coast Biotech Virtual Bus Tour on March 16, and Oppenheimer's Healthcare Conference on March 17. A live audio webcast will be accessible through the IDEAYA website, and recordings will be available for 30 days post-event. IDEAYA specializes in developing targeted therapeutics using synthetic lethality.
IDEAYA Biosciences (NASDAQ: IDYA) announced its first Synthetic Lethality Investor Day, scheduled for April 20, 2021. This virtual event will feature presentations from IDEAYA, GlaxoSmithKline (GSK), and key academic leaders. The agenda includes discussions on IDEAYA's synthetic lethality programs, particularly IDE397, a Phase 1 clinical trial targeting MAT2A in MTAP-deleted tumors, a condition found in around 15% of solid tumors. The event aims to engage scientific and investor communities regarding advancements in precision medicine.
IDEAYA Biosciences (NASDAQ: IDYA) announced the appointment of Dr. Susan Kelley to its Board of Directors, enhancing its leadership in oncology research. Dr. Kelley brings over 25 years of experience, notably as Chief Medical Officer at the Multiple Myeloma Research Consortium, and previous roles at Bayer and Bristol-Myers Squibb. Her expertise will support the advancement of IDEAYA's clinical programs, including the Phase 1 IDE397 and potential Phase 2 expansion for IDE196. This strategic addition aims to strengthen IDEAYA's pipeline of precision medicine oncology therapies.
IDEAYA Biosciences (NASDAQ: IDYA) announced the successful IND application for IDE397, a MAT2A inhibitor, enabling a Phase 1 clinical trial for cancer patients with MTAP deletion, found in 15% of solid tumors. The trial is set to begin in Q1 2021. Additionally, Matthew Maurer, M.D., has joined as Vice President, bringing over 15 years of oncology experience. His expertise will support the advancement of IDE397 and the company's PARG program. The announcement highlights IDEAYA's commitment to targeted therapeutics in precision medicine and the ongoing development of its synthetic lethality pipeline.
IDEAYA Biosciences (Nasdaq: IDYA) announced its participation in two key investor relations events in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day will include a fireside chat with analyst Michael Schmidt on February 12 at 12:00 pm ET, while the LifeSci Partners Precision Oncology Event is scheduled for February 17 at 2:00 pm ET. Live audio webcasts of both presentations will be accessible on the IDEAYA website and will be available for replay for 30 days.
IDEAYA Biosciences (Nasdaq: IDYA) has partnered with Spelman College to develop the next generation of female African American leaders in biotechnology. This initiative includes mentorship, internships, and scholarships for selected students. Participants will receive industry-focused education and career guidance. IDEAYA aims to support these students financially and professionally, contributing to the future of oncology-focused precision medicine, particularly in addressing health disparities among people of African descent.
IDEAYA Biosciences (Nasdaq:IDYA) has submitted an Investigational New Drug (IND) application to the FDA for IDE397, a MAT2A inhibitor aimed at treating solid tumors with MTAP deletion. This marks a significant milestone in IDEAYA's research pipeline focused on synthetic lethality therapies. Approximately 15% of solid tumors have the MTAP deletion, representing a potential patient population for IDE397. IDEAYA will share further details at the 39th Annual J.P. Morgan Healthcare Conference, including preclinical data showing tumor regressions and proposed clinical plans.
FAQ
What is the current stock price of IDEAYA Biosciences (IDYA)?
What is the market cap of IDEAYA Biosciences (IDYA)?
What is IDEAYA Biosciences, Inc.?
What is the primary focus of IDEAYA's research?
What is IDEAYA's product pipeline?
Who are IDEAYA's key investors?
Where is IDEAYA Biosciences located?
What recent collaborations has IDEAYA announced?
What significant achievements has IDEAYA made recently?
What is IDEAYA's financial outlook?
Who comprises IDEAYA's scientific advisory board?
How can I stay updated on IDEAYA Biosciences?
